Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385668021> ?p ?o ?g. }
- W4385668021 endingPage "372" @default.
- W4385668021 startingPage "364" @default.
- W4385668021 abstract "Purpose of review Patients with relapsed/refractory primary central nervous system lymphoma (rrPCNSL) have poor prognosis, with a median survival after relapse of 6.8 months. In this review, we discuss the evolving landscape and the possible future directions related to this important unmet clinical need. Recent findings The modern two-phase approach for newly diagnosed PCNSL based on an induction using high-dose methotrexate (HD-MTX) combinations and a subsequent consolidation, has significantly improved the outcome in this setting. However, this strategy is able to cure more or less 50% of patients. rrPCNSL patients have a very poor prognosis with a reported 5-year overall survival of 18%. Late relapses (after third year) and use of high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) represent important factors associated with a better outcome in this setting. On the basis of the growing acquisition of knowledge on the molecular characteristics of PCNSL, the use of non-chemotherapeutic drugs such as bruton tyrosine kinase inhibitors (BTK-is), immunomodulatory drugs (IMiDs) and immune checkpoint blockers (ICBs) is increasing in the last years along with the introduction of novel approaches (CAR-T cells and blood--brain barrier disruption). However, despite high responses in some cases, durations are often short, translating in outcome results still unsatisfactory. Summary Treatment of rrPCNSL patients is challenging. As no standard of care exist in this setting, it is of paramount importance to acquire new knowledge related to this condition and start multidisciplinary collaboration in order to improve pts outcome." @default.
- W4385668021 created "2023-08-09" @default.
- W4385668021 creator A5002203533 @default.
- W4385668021 creator A5032242664 @default.
- W4385668021 creator A5036985315 @default.
- W4385668021 creator A5050937741 @default.
- W4385668021 date "2023-07-18" @default.
- W4385668021 modified "2023-09-26" @default.
- W4385668021 title "New hopes in relapsed refractory primary central nervous system lymphoma" @default.
- W4385668021 cites W1546262304 @default.
- W4385668021 cites W1608441558 @default.
- W4385668021 cites W1973157288 @default.
- W4385668021 cites W1979816280 @default.
- W4385668021 cites W1989568854 @default.
- W4385668021 cites W2003105250 @default.
- W4385668021 cites W2007540726 @default.
- W4385668021 cites W2013617883 @default.
- W4385668021 cites W2033939995 @default.
- W4385668021 cites W2047395808 @default.
- W4385668021 cites W2054244489 @default.
- W4385668021 cites W2055926684 @default.
- W4385668021 cites W2059495814 @default.
- W4385668021 cites W2082969877 @default.
- W4385668021 cites W2095946215 @default.
- W4385668021 cites W2096005492 @default.
- W4385668021 cites W2120766517 @default.
- W4385668021 cites W2122782894 @default.
- W4385668021 cites W2129831897 @default.
- W4385668021 cites W2137578993 @default.
- W4385668021 cites W2151600550 @default.
- W4385668021 cites W2170138469 @default.
- W4385668021 cites W2170352017 @default.
- W4385668021 cites W2174885799 @default.
- W4385668021 cites W2294816409 @default.
- W4385668021 cites W2297585449 @default.
- W4385668021 cites W2314481096 @default.
- W4385668021 cites W2600581432 @default.
- W4385668021 cites W2617804822 @default.
- W4385668021 cites W2617968907 @default.
- W4385668021 cites W2618939391 @default.
- W4385668021 cites W2625473279 @default.
- W4385668021 cites W2746068181 @default.
- W4385668021 cites W2761111503 @default.
- W4385668021 cites W2773804840 @default.
- W4385668021 cites W2788138754 @default.
- W4385668021 cites W2793645303 @default.
- W4385668021 cites W2843787264 @default.
- W4385668021 cites W2884596048 @default.
- W4385668021 cites W2894051390 @default.
- W4385668021 cites W2903062212 @default.
- W4385668021 cites W2903225254 @default.
- W4385668021 cites W2903669497 @default.
- W4385668021 cites W2912416355 @default.
- W4385668021 cites W2914256533 @default.
- W4385668021 cites W2917478934 @default.
- W4385668021 cites W2946633993 @default.
- W4385668021 cites W2954436306 @default.
- W4385668021 cites W2963496214 @default.
- W4385668021 cites W2979984433 @default.
- W4385668021 cites W2980032048 @default.
- W4385668021 cites W2984776263 @default.
- W4385668021 cites W2985376593 @default.
- W4385668021 cites W2997386338 @default.
- W4385668021 cites W2998287398 @default.
- W4385668021 cites W3019295614 @default.
- W4385668021 cites W3037142274 @default.
- W4385668021 cites W3047919114 @default.
- W4385668021 cites W3093859834 @default.
- W4385668021 cites W3094967851 @default.
- W4385668021 cites W3096678748 @default.
- W4385668021 cites W3171975865 @default.
- W4385668021 cites W3178168040 @default.
- W4385668021 cites W3192904398 @default.
- W4385668021 cites W3196301278 @default.
- W4385668021 cites W3196726943 @default.
- W4385668021 cites W3201013983 @default.
- W4385668021 cites W3203450602 @default.
- W4385668021 cites W4200007083 @default.
- W4385668021 cites W4200335577 @default.
- W4385668021 cites W4213165752 @default.
- W4385668021 cites W4220921975 @default.
- W4385668021 cites W4223991347 @default.
- W4385668021 cites W4229445130 @default.
- W4385668021 cites W4280628141 @default.
- W4385668021 cites W4280648573 @default.
- W4385668021 cites W4282982621 @default.
- W4385668021 cites W4283314494 @default.
- W4385668021 cites W4283733476 @default.
- W4385668021 cites W4285007096 @default.
- W4385668021 cites W4285391064 @default.
- W4385668021 cites W4297201049 @default.
- W4385668021 cites W4301595791 @default.
- W4385668021 cites W4306843034 @default.
- W4385668021 cites W4308371570 @default.
- W4385668021 cites W4309437150 @default.
- W4385668021 cites W4310107647 @default.
- W4385668021 cites W4310119335 @default.
- W4385668021 cites W4310125682 @default.